Lapatinib is a novel oral dual tyrosine kinase inhibitor (TKI), it can also inhibit the epidermal growth factor receptor (EGFR) and epidermal growth factor receptor -2 (HER-2) of tyrosine kinase activity. Lapatinib preclinical and clinical results show that: lapatinib in vitro and in vivo experiments have also shown that certain anti-tumor activity. Lapatinib for breast cancer patients, especially monoclonal antibodies trastuzumab resistant locally advanced and metastatic breast cancer patients showed a better effect. TKI represented by lapatinib treatment of breast cancer is expected to open up a new way.
Lapatinib treatment of breast cancer research
ReplyDeleteLapatinib is a novel oral dual tyrosine kinase inhibitor (TKI), it can also inhibit the epidermal growth factor receptor (EGFR) and epidermal growth factor receptor -2 (HER-2) of tyrosine kinase activity. Lapatinib preclinical and clinical results show that: lapatinib in vitro and in vivo experiments have also shown that certain anti-tumor activity. Lapatinib for breast cancer patients, especially monoclonal antibodies trastuzumab resistant locally advanced and metastatic breast cancer patients showed a better effect. TKI represented by lapatinib treatment of breast cancer is expected to open up a new way.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
HIV-1 integrase inhibitor
BMS-707035
Nelfinavir
Tezampanel
NS309
Vernakalant
Vernakalant Hydrochloride
Dronedarone hydrochloride
Dronedarone
Ruxolitinib